ReviewNanotheranostics2022
Advances in Surface Enhanced Raman Spectroscopy for
Review in Nanotheranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Raman reporters for SERS/SERRS biosensing and biomedicine: design, applications, and challenges.Mikrochimica acta · 2026Review
- Advanced integrated SERS-based strategies for the early diagnosis of upper gastrointestinal cancers.Journal of nanobiotechnology · 2026Review
- Article
- Application Advances of Gold Nanoparticles in Cancer Theranostics: From Physicochemical Mechanisms to Multifunctional Nanoplatforms.International journal of molecular sciences · 2026Review
- Simultaneous detection of lymphocytes and tumor cellsNanoscale horizons · 2026Article
- SERS-guided photodynamic therapy: pioneering strategies in advanced cancer diagnosis and treatment.Discover nano · 2025Review
- Surface-Enhanced Raman Spectroscopy for Biomedical Applications: Recent Advances and Future Challenges.ACS applied materials & interfaces · 2025Review
- In vivo surface-enhanced Raman scattering techniques: nanoprobes, instrumentation, and applications.Light, science & applications · 2025Review
- Review
- Non-invasive applications of Raman spectroscopy in assisted reproduction.Frontiers in endocrinology · 2025Review
- Nanoparticle Uptake in the Aging and OncogenicCells · 2024Article
- In vivo imaging using surface enhanced spatially offset raman spectroscopy (SESORS): balancing sampling frequency to improve overall image acquisition.Npj imaging · 2024Article
- Engineered aptamers for molecular imaging.Chemical science · 2023Review
- Synergies in antimicrobial treatment by a levofloxacin-loaded halloysite and gold nanoparticles with a conjugation to a cell-penetrating peptide.Nanoscale advances · 2022Article
- Environmental protection based on the nanobiosensing of bacterial lipopolysaccharides (LPSs): material and method overview.RSC advances · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In the last two decades, the application of surface enhanced Raman scattering (SERS) nanoparticles for preclinical cancer imaging has attracted increasing attention. Raman imaging with SERS nanoparticles offers unparalleled sensitivity, providing a platform for molecular targeting, and granting multiplexed and multimodal imaging capabilities. Recent progress has been facilitated not only by the optimization of the SERS contrast agents themselves, but also by the developments in Raman imaging approaches and instrumentation. In this article, we review the principles of Raman scattering and SERS, present advances in Raman instrumentation specific to cancer imaging, and discuss the biological means of ensuring selective
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.